Medtronic's Infuse Tied To Male Infertility Risks

Law360, New York (May 25, 2011, 7:16 PM EDT) -- A medical study released Wednesday suggested that the use of Medtronic Inc.'s popular bone growth product Infuse in some spine surgeries may increase the risk of male infertility.

Eugene J. Carragee of the Stanford School of Medicine, the lead author of the study published in The Spine Journal, said in a statement that while male infertility has long been a known risk in some spine surgeries, spinal fusion procedures using rhBMP-2 — a manufactured protein and the active ingredient in Infuse — appears to be greater...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.